Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12005663 | 0.92 | SIRT6 (0.63) | SIRT6LMNAHTR7MAPTALDH1A1 | |
| SCHEMBL6945690 | 0.85 | SIRT6 (0.65) | SIRT6LMNAHTR7MAPTALDH1A1 | |
| SCHEMBL2730000 | 0.82 | KDM4E (0.63) | SIRT6LMNAMAPTALDH1A1HTR1A | |
| SCHEMBL5743368 | 0.82 | HTR1A (0.61) | SIRT6LMNAMAPTHTR1APOLB | |
| SCHEMBL5187796 | 0.82 | SIRT6 (0.60) | SIRT6LMNAMAPTHTR1APOLB | |
| SCHEMBL1045292 | 0.81 | SIRT6 (0.69) | SIRT6LMNAHTR7MAPTALDH1A1 | |
| SCHEMBL5209234 | 0.81 | MAPT (0.67) | SIRT6LMNAMAPTHTR1APOLB | |
| SCHEMBL3187195 | 0.81 | SIRT6 (0.59) | SIRT6LMNAMAPTHTR1APOLB | |
| SCHEMBL12431530 | 0.80 | MAPT (0.70) | SIRT6LMNAMAPTALDH1A1HTR1A | |
| SCHEMBL19926115 | 0.80 | HTR1A (0.58) | SIRT6LMNAMAPTHTR1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1664053-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682531-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1664053-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1654238-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005042518-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050070554-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005021551-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005009978-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | SIRT6 2716/4885LMNA 4524/4885HTR7 1359/4885 |
| US-20050070554-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, PAICS | SIRT6 711/4885LMNA 4237/4885HTR7 735/4885 |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | SIRT6 3016/4885LMNA 3229/4885HTR7 4221/4885 |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | SIRT6 3760/4885LMNA 4131/4885HTR7 154/4885 |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | SIRT6 3210/4885LMNA 4129/4885HTR7 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.